Prenatal Screening for CMV Primary Infection: A Cost-Utility Model

Gebrael El Hachem1, Christian Renaud, Catherine McCarey

  • 1School of Public Health, Université de Montréal (G.E.H., T.G.P., I.B.); Women and Children's Infectious Diseases Center, CHU Sainte-Justine Research Center (G.E.H., C.R., C.M., S.G., F.K., I.B.); Research Center of the IUSMM, CIUSSS de l'Est de l'Île de Montréal (T.G.P.); and Departments of Obstetrics and Gynecology (C.M.) and Pediatrics (C.R., S.G., F.K.), Université de Montréal, Montreal, Quebec, Canada; and Faculty of Medicine, Université Catholique de Louvain, Brussels, Belgium (M.S.).

PubMed
Summary

Congenital cytomegalovirus (cCMV) affects approximately 1 in 200 Canadian newborns. This infection can lead to serious neurodevelopmental disabilities in children.